Showing results (191-200 of 208) with videos related to

Sort By:
Pageof 21
The New England Journal of Medicine|September 28, 2017
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell LymphomaSteven Le Gouill, Catherine Thieblemont, Lucie Oberic, et al.
Blood Cancer Journal|April 24, 2025
Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA studyClémentine Sarkozy, Loïc Chartier, Vincent Ribrag, et al.
Blood|November 19, 2020
Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSASteven Le Gouill, Hervé Ghesquières, Lucie Oberic, et al.
American Journal of Hematology|January 6, 2023
Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 studyJean-Marie Michot, Cyril Quivoron, Clémentine Sarkozy, et al.
Cancer|November 2, 2021
Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphomaNicolas Leupin, Pier Luigi Zinzani, Franck Morschhauser, et al.
Leukemia|April 27, 2024
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma networkLuca Fischer, Linmiao Jiang, Jan Dürig, et al.
Blood|January 25, 2020
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifierCecilia Carpio, Reda Bouabdallah, Loïc Ysebaert, et al.
Cancer Discovery|April 3, 2017
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 TrialChristophe Massard, Stefan Michiels, Charles Ferté, et al.
The Lancet. Haematology|December 12, 2018
Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational studyNicolas Delanoy, Jean-Marie Michot, Thibault Comont, et al.
Lancet (London, England)|June 18, 2016
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Eva Hoster, Jan Walewski, et al.
Pageof 21